Sartorius (SRT3) PT Set at €142.00 by UBS Group

UBS Group set a €142.00 ($165.12) price target on Sartorius (FRA:SRT3) in a research report report published on Tuesday morning, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the stock.

Several other brokerages also recently weighed in on SRT3. Berenberg Bank set a €110.00 ($127.91) target price on Sartorius and gave the company a neutral rating in a research note on Thursday, October 18th. Commerzbank set a €101.00 ($117.44) target price on Sartorius and gave the company a sell rating in a research note on Friday, October 19th. Warburg Research set a €141.00 ($163.95) target price on Sartorius and gave the company a neutral rating in a research note on Tuesday. Finally, HSBC set a €99.00 ($115.12) target price on Sartorius and gave the company a sell rating in a research note on Thursday, October 18th. Four analysts have rated the stock with a sell rating and five have issued a hold rating to the company. Sartorius has an average rating of Hold and an average target price of €107.39 ($124.87).

Shares of Sartorius stock opened at €120.60 ($140.23) on Tuesday. Sartorius has a 1-year low of €71.00 ($82.56) and a 1-year high of €124.70 ($145.00).



About Sartorius

Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.

Featured Story: What is a Fiduciary?

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply